{"id":53286,"date":"2026-01-08T01:02:02","date_gmt":"2026-01-07T17:02:02","guid":{"rendered":"https:\/\/flcube.com\/?p=53286"},"modified":"2026-01-08T01:02:03","modified_gmt":"2026-01-07T17:02:03","slug":"structure-therapeutics-licenses-glp-1-patents-to-roche-for-100-million-upfront","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53286","title":{"rendered":"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront"},"content":{"rendered":"\n

Structure Therapeutics Inc.<\/strong> (NASDAQ: GPCR<\/a>) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio<\/strong>, entered into a licensing agreement with Genentech Inc.<\/strong> and F. Hoffmann\u2011La Roche Ltd (Roche)<\/strong> on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access<\/strong> to specific patents covering oral GLP\u20111 receptor agonists<\/strong> for an upfront payment of USD\u202f100\u202fmillion<\/strong>, plus low single\u2011digit royalties on net sales of CT\u2011996<\/strong>, Roche’s oral GLP\u20111 candidate.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Structure Therapeutics Inc. (via Gasherbrum Bio)<\/td><\/tr>
Licensees<\/strong><\/td>Genentech Inc. and F.\u202fHoffmann\u2011La Roche Ltd (Roche)<\/td><\/tr>
Asset<\/strong><\/td>Patents covering oral GLP\u20111 receptor agonists<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD\u202f100\u202fmillion<\/td><\/tr>
Royalties<\/strong><\/td>Low single\u2011digit on CT\u2011996 net sales<\/td><\/tr>
License Type<\/strong><\/td>Non\u2011exclusive<\/td><\/tr>
Agreement Date<\/strong><\/td>Dec\u202f30,\u202f2025 (announced Jan\u202f5,\u202f2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Key Deal Terms<\/h2>\n\n\n\n

Non\u2011Exclusive License<\/strong>: Structure Therapeutics retains full rights<\/strong> to its internal R&D programs and maintains flexibility to license the IP to other partners in the future.<\/p>\n\n\n\n

Patent Covenants<\/strong>: Structure Therapeutics agrees not to assert specific future patent claims<\/strong> against the manufacturing or sale of Roche’s CT\u2011996 product.<\/p>\n\n\n\n

Enforcement Rights<\/strong>: Genentech and Roche do not have the right to lead or execute litigation<\/strong> to enforce the licensed patents; these rights remain exclusively with Structure Therapeutics<\/strong>.<\/p>\n\n\n\n

Strategic Context<\/h2>\n\n\n\n

GLP\u20111 Market Dynamics<\/strong>: The global GLP\u20111 receptor agonist market is valued at $30\u202fbillion<\/strong> (2025) and projected to reach $70\u202fbillion by 2030<\/strong>, driven by obesity and diabetes treatments. Oral formulations represent a high\u2011value segment<\/strong> due to patient convenience.<\/p>\n\n\n\n

Roche’s Position<\/strong>: Roche is developing CT\u2011996 as its entry into the lucrative GLP\u20111 space, competing with Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy. Securing IP rights from Structure Therapeutics de\u2011risks development<\/strong> and accelerates time\u2011to\u2011market.<\/p>\n\n\n\n

Structure’s IP Portfolio<\/strong>: The company has built a robust patent estate<\/strong> around oral GLP\u20111 receptor agonists, making it a strategic gatekeeper<\/strong> in this competitive field.<\/p>\n\n\n\n

Financial Implications<\/h2>\n\n\n\n

Near\u2011Term Cash<\/strong>: The $100\u202fmillion upfront payment provides Structure Therapeutics with non\u2011dilutive capital<\/strong> to advance its internal pipeline.<\/p>\n\n\n\n

Long\u2011Term Royalties<\/strong>: Low single\u2011digit royalties on CT\u2011996 sales could generate $50\u2011100\u202fmillion annually<\/strong> once Roche’s product reaches peak sales, assuming $2\u20113\u202fbillion in global revenues.<\/p>\n\n\n\n

Platform Value<\/strong>: The deal validates Structure’s technology platform<\/strong> and may attract additional licensing partners, creating a recurring revenue stream.<\/p>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Company<\/th>Oral GLP\u20111 Asset<\/th>Stage<\/th>Market Position<\/th><\/tr><\/thead>
Roche\/Genentech<\/strong><\/td>CT\u2011996<\/td>Phase\u202fII\/III<\/td>Development with licensed IP<\/td><\/tr>
Eli Lilly<\/strong><\/td>Orforglipron<\/td>Phase\u202fIII<\/td>First oral small molecule<\/td><\/tr>
Novo Nordisk<\/strong><\/td>Oral semaglutide<\/td>Marketed<\/td>Leader in injectables<\/td><\/tr>
Pfizer<\/strong><\/td>Danuglipron<\/td>Discontinued<\/td>Competitive pressure<\/td><\/tr>
Structure Therapeutics<\/strong><\/td>Internal programs<\/td>Discovery<\/td>IP licensor + developer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding the deal’s financial impact, Roche’s CT\u2011996 development timeline, and Structure Therapeutics’ ability to secure additional licensing agreements. Actual results may differ materially due to competitive dynamics, patent enforcement outcomes, and GLP\u20111 market evolution.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4539,4361,4538,163,3264],"class_list":["post-53286","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gasherbrum-bio","tag-hot-targets","tag-nasdaq-gpcr","tag-roche","tag-structure-therapeutics"],"yoast_head":"\nStructure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a licensing agreement with Genentech Inc. and F. Hoffmann\u2011La Roche Ltd (Roche) on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access to specific patents covering oral GLP\u20111 receptor agonists for an upfront payment of USD\u202f100\u202fmillion, plus low single\u2011digit royalties on net sales of CT\u2011996, Roche's oral GLP\u20111 candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53286\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront\" \/>\n<meta property=\"og:description\" content=\"Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a licensing agreement with Genentech Inc. and F. Hoffmann\u2011La Roche Ltd (Roche) on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access to specific patents covering oral GLP\u20111 receptor agonists for an upfront payment of USD\u202f100\u202fmillion, plus low single\u2011digit royalties on net sales of CT\u2011996, Roche's oral GLP\u20111 candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53286\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T17:02:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T17:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53286#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53286\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront\",\"datePublished\":\"2026-01-07T17:02:02+00:00\",\"dateModified\":\"2026-01-07T17:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53286\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gasherbrum Bio\",\"Hot targets\",\"NASDAQ: GPCR\",\"Roche\",\"Structure Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53286#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53286\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53286\",\"name\":\"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T17:02:02+00:00\",\"dateModified\":\"2026-01-07T17:02:03+00:00\",\"description\":\"Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a licensing agreement with Genentech Inc. and F. Hoffmann\u2011La Roche Ltd (Roche) on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access to specific patents covering oral GLP\u20111 receptor agonists for an upfront payment of USD\u202f100\u202fmillion, plus low single\u2011digit royalties on net sales of CT\u2011996, Roche's oral GLP\u20111 candidate.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53286#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53286\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53286#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront - Insight, China's Pharmaceutical Industry","description":"Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a licensing agreement with Genentech Inc. and F. Hoffmann\u2011La Roche Ltd (Roche) on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access to specific patents covering oral GLP\u20111 receptor agonists for an upfront payment of USD\u202f100\u202fmillion, plus low single\u2011digit royalties on net sales of CT\u2011996, Roche's oral GLP\u20111 candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53286","og_locale":"en_US","og_type":"article","og_title":"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront","og_description":"Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a licensing agreement with Genentech Inc. and F. Hoffmann\u2011La Roche Ltd (Roche) on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access to specific patents covering oral GLP\u20111 receptor agonists for an upfront payment of USD\u202f100\u202fmillion, plus low single\u2011digit royalties on net sales of CT\u2011996, Roche's oral GLP\u20111 candidate.","og_url":"https:\/\/flcube.com\/?p=53286","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T17:02:02+00:00","article_modified_time":"2026-01-07T17:02:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53286#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53286"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront","datePublished":"2026-01-07T17:02:02+00:00","dateModified":"2026-01-07T17:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53286"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gasherbrum Bio","Hot targets","NASDAQ: GPCR","Roche","Structure Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53286#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53286","url":"https:\/\/flcube.com\/?p=53286","name":"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T17:02:02+00:00","dateModified":"2026-01-07T17:02:03+00:00","description":"Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly\u2011owned subsidiary, Gasherbrum Bio, entered into a licensing agreement with Genentech Inc. and F. Hoffmann\u2011La Roche Ltd (Roche) on December\u202f30,\u202f2025. The deal grants Roche non\u2011exclusive access to specific patents covering oral GLP\u20111 receptor agonists for an upfront payment of USD\u202f100\u202fmillion, plus low single\u2011digit royalties on net sales of CT\u2011996, Roche's oral GLP\u20111 candidate.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53286#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53286"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53286#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53286"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53286\/revisions"}],"predecessor-version":[{"id":53288,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53286\/revisions\/53288"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}